[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Pages 2579-2580]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01507]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Johnson
Matthey Pharmaceutical Materials, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before April 8, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701
[[Page 2580]]
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
November 8, 2018, Johnson Matthey Pharmaceutical Materials, Inc., 25
Patton Road, Devens, Massachusetts 01434 applied to be registered as a
bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Controlled substances Drug code Schedule
------------------------------------------------------------------------
Amphetamine........................... 1100 II
Methylphenidate....................... 1724 II
Nabilone.............................. 7379 II
Hydrocodone........................... 9193 II
Levorphanol........................... 9220 II
Alfentanil............................ 9737 II
Remifentanil.......................... 9739 II
Sufentanil............................ 9740 II
------------------------------------------------------------------------
The company plans to support its other manufacturing facilities
located in West Deptford, New Jersey and Conshohocken, Pennsylvania
with manufacturing and analytical testing.
Dated: December 21, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-01507 Filed 2-6-19; 8:45 am]
BILLING CODE 4410-09-P